Halozyme Therapeutics (HALO) Other financing activities (2010 - 2021)
Halozyme Therapeutics (HALO) posted quarterly Other financing activities of $4.3 million for Q4 2021, down 66.19% year-over-year from $12.7 million in Q4 2020, and down 7.27% quarter-over-quarter from $4.6 million in Q3 2021.
Halozyme Therapeutics (HALO) Other financing activities (2010 - 2021) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Other financing activities for 12 consecutive years, with $4.3 million the latest figure, recorded in Q4 2021.
- In Q4 2021, Other financing activities fell 66.19% year-over-year to $4.3 million; the TTM figure through Dec 2021 stood at $12.5 million (down 80.22% YoY), while the FY2022 annual figure was $14.0 million, up 12.08% from the prior year.
- Other financing activities retreated to $4.3 million in Q4 2021 per HALO's latest filing, from $4.6 million in the prior quarter.
- Across five years, Other financing activities topped out at $19.7 million in Q1 2020 and bottomed at -$602000.0 in Q1 2021.
- Historically, Other financing activities has averaged $5.8 million across 5 years, with a median of $4.3 million in 2017.
- Annual changes were most pronounced in 2017 — Other financing activities slumped 237.89% — and 2020, when it surged 4491.31%.
- Halozyme Therapeutics' Other financing activities stood at $5.1 million in 2017, then sank by 59.47% to $2.1 million in 2018, then soared by 294.13% to $8.1 million in 2019, then jumped by 56.78% to $12.7 million in 2020, then sank by 66.19% to $4.3 million in 2021.
- Business Quant data shows HALO's Other financing activities at $4.3 million in Q4 2021, $4.6 million in Q3 2021, and $4.2 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 4.31 Mn |
| Dec 31, 2021 | 4.31 Mn |
| Sep 30, 2021 | 4.65 Mn |
| Sep 30, 2021 | 4.65 Mn |
| Jun 30, 2021 | 4.18 Mn |
| Jun 30, 2021 | 4.18 Mn |
| Mar 31, 2021 | -602,000.00 |
| Mar 31, 2021 | -602,000.00 |
| Dec 31, 2020 | 12.75 Mn |
| Dec 31, 2020 | 12.75 Mn |
| Sep 30, 2020 | 12.55 Mn |
| Sep 30, 2020 | 12.55 Mn |
| Jun 30, 2020 | 18.38 Mn |
| Jun 30, 2020 | 18.38 Mn |
| Mar 31, 2020 | 19.72 Mn |
| Mar 31, 2020 | 19.72 Mn |
| Dec 31, 2019 | 8.13 Mn |
| Dec 31, 2019 | 8.13 Mn |
| Sep 30, 2019 | 2.08 Mn |
| Sep 30, 2019 | 2.08 Mn |